ABUS vs AGIO Stock Comparison

ABUS currently leads AGIO in this stock comparison, with AIQ scores of 70 vs 56. The clearest difference is value, while AGIO has the stronger momentum profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 14 points
ABUS
Healthcare
vs
AGIO
Healthcare
ABUS
Arbutus Biopharma Corp
Leads
Price
$4.09
Day move
+1.49%
AIQ Score
70/100
Best edge
Value
Sector
Healthcare
AGIO
Agios Pharmaceuticals, Inc.
Price
$31.59
Day move
-0.54%
AIQ Score
56/100
Best edge
Momentum
Sector
Healthcare

What is the main difference between ABUS and AGIO?

ABUS leads the current stock comparison as Arbutus Biopharma Corp, with the clearest separation coming from value and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Arbutus Biopharma Corp vs Agios Pharmaceuticals, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 61/66 fields· High confidence
AIQ VerdictStableAIQ Comparison Conviction 8/10

ABUS leads

ABUS leads by 14 AIQ points, primarily on Value and Quality, but the lead has narrowed from 19 points over 30 sessions.

Stable: 4 of 5 evidence groups support ABUS, its lead is narrowing, and its current signal state is conflicted.

Evidence agreement: 4 of 5Comparison trend: Weakening
ABUS

Arbutus Biopharma Corp

Leads
AIQ Score
70/100
AIQ Edge Score
9/10
AGIO

Agios Pharmaceuticals, Inc.

AIQ Score
56/100
AIQ Edge Score
5/10

The Algovestiq AIQ Score currently favors ABUS over AGIO, 70 versus 56 as of Nov 15, 2026. ABUS's advantage is driven primarily by stronger value and quality, while AGIO holds the stronger momentum profile. ABUS also shows the weaker technical structure relative to its 50-day moving average. 4 of 5 covered evidence groups favor ABUS today, and the comparison is rated Stable on stability: the leader's advantage has been narrowing. ABUS lead: Weakening — the AIQ differential moved from 19 to 14 points over 30 sessions.

Compare Arbutus Biopharma Corp and Agios Pharmaceuticals, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

ABUS
+24.3%
AGIO
-20.4%

Price return comparison

Growth of $10,000, price only

ABUS $12,432 · AGIO $7,963

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare ABUS and AGIO against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

ABUS advantage
0
AGIO advantage
  • Value92 vs 52
    ABUS +40
  • Quality82 vs 58
    ABUS +24
  • Risk Resilience62 vs 47
    ABUS +15
  • Momentum51 vs 61
    AGIO +10

4 of 5 evidence groups favor ABUS. ABUS’s edge is concentrated in value and quality; AGIO keeps a meaningful momentum edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

ABUS0 AIQ

No factor moved materially.

New signals

  • Death Cross Active — bearish, trend, long horizon (0.45%)
  • Downtrend Structure Active — bearish, trend, long horizon
AGIO0 AIQ

Largest factor move: Quality +1, not enough on its own to move the overall score.

New signals

  • Low Volume Rally Warning — bearish, volume, short horizon (0.30x)

ABUS's lead was unchanged in the latest session.

Deeper signal detail for each name lives on its own signals page — ABUS and AGIO both carry a full feed there.

The central trade-off

ABUS (Arbutus Biopharma Corp): the stronger current systematic profile, led by value and quality.

AGIO (Agios Pharmaceuticals, Inc.): the counter-case, on momentum, technicals — but at materially higher volatility, 96.3% against 52.1%.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

ABUS

ABUS on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

AGIO

AGIO on combined revenue and EPS growth.

Value

ABUS

ABUS on the peer-relative Value factor, by 40 points.

Momentum

AGIO

AGIO on the Momentum factor, by 10 points.

Lower downside

ABUS

ABUS on Risk Resilience, by 15 points.

Analyst upside

Even

Analyst targets are level or not covered for both names.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureABUSAGIONote
Implied upside to target—+10.8%Level
Target dispersion—0%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering110Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

4 of 5 covered evidence groups favor ABUS. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreABUS70 vs 56
FundamentalsABUSon balancerevenue growth -70.5% vs 23.8%; EPS growth 11% vs 35.5%; TTM ROE 68.9% vs -6.6%; gross margin 100% vs 91.9%; operating margin 79.9% vs -297.7% — ABUS takes 3 of 5 decided legs, not all of them
ValuationABUSValue 92 vs 52
TechnicalsAGIOPrice vs 50-day -8.3% vs -4.5%; vs 200-day -8.7% vs -0.8%
Risk ResilienceABUSRisk Resilience 62 vs 47
Analyst expectationsNot coveredNot covered

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of ABUS and AGIO and are excluded from the count.

AIQ Decision Stability

Stable

The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.

  • The AIQ gap is wide at 14 points. (supports the conclusion holding)
  • 4 of 5 covered evidence groups point the same way. (supports the conclusion holding)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ABUS.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

ABUS lead: Weakening — the AIQ differential moved from 19 to 14 points over 30 sessions.

May 27ABUS leads above the line · AGIO leads belowNov 13
Today
ABUS +14
70 vs 56
7 sessions ago
ABUS +11
68 vs 57
30 sessions ago
ABUS +19
68 vs 49
90 sessions ago
ABUS +14
72 vs 58

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

ABUSConflicted

2 bullish / 3 bearish / 1 neutral, conflicted

Only ABUS

  • Death Cross Active — bearish, trend, long horizon (0.45%)
  • Distribution Pattern — bearish, volume, medium horizon (1.36x)
  • Downtrend Structure Active — bearish, trend, long horizon
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
  • OBV Bullish Divergence — bullish, volume, medium horizon (-3.1%)
AGIOConflicted

1 bullish / 2 bearish / 2 neutral, conflicted

Only AGIO

  • Golden Cross Active — bullish, trend, long horizon (3.90%)
  • ADX Trend Weakening — neutral, trend, medium horizon
  • Beta Spike Warning — bearish, risk_regime, long horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.30x)

Both carry 1 more signal that do not separate them: ATR Expansion - Breakout Mode.

ABUS leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

ABUSNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.49%, AIQ 0 points).

AGIONo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.54%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1AGIO closes the Value gap — currently 40 points behind, the largest single contributor to ABUS's edge.
  2. 2AGIO's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
  3. 3ABUS's conflicting signal state resolves bearish — it currently carries 2 bullish and 3 bearish rules at once.
  4. 4The narrowing continues — the lead has already given back 5 points over 30 sessions, and a further 14-point move would eliminate ABUS's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

ABUS leads on balance
MetricABUSAGIO
Revenue growth (YoY)-70.5%23.8%
EPS growth (YoY)11%35.5%
Gross margin100%91.9%
Operating margin79.9%-297.7%
Return on equity (TTM)68.9%-6.6%
Debt to equity00.03

Performance

AGIO leads 4 of 6 windows
MetricABUSAGIO
1 week (5 sessions)11.9%7.4%
1 month (20 sessions)-3.1%0.9%
3 months (63 sessions)-13.2%-6.1%
6 months (126 sessions)-3.5%12.1%
Year to date-15%16.1%
1 year (252 sessions)-15.5%-27.6%

Technicals

AGIO has the stronger structure
MetricABUSAGIO
RSI (14)48.546.3
ADX (14)29.220.6
Price vs 50-day-8.3%-4.5%
Price vs 200-day-8.7%-0.8%
Volatility (1M, annualized)52.1%96.3%

Risk

ABUS is the more resilient
MetricABUSAGIO
Beta1.190.93
Sharpe ratio-0.090.07
Sortino ratio-0.130.08
Max drawdown-30%-50.9%
Current drawdown-21.6%-30.6%
Annualized volatility45.9%80%
Value at risk (95%)-4.4%-3.9%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, ABUS or AGIO?

On the Algovestiq AIQ Score, ABUS is the stronger of the two as of Nov 15, 2026, scoring 70 against AGIO's 56. The edge comes from value and quality. AGIO is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is ABUS or AGIO the better buy right now?

ABUS carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 4 of 5 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.

Why does the AIQ Score favor ABUS over AGIO?

The composite weights Quality, Value, Momentum and Risk Resilience. ABUS leads Value by 40 points; ABUS leads Quality by 24 points; ABUS leads Risk Resilience by 15 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, ABUS or AGIO?

Analyst price targets imply not covered upside for ABUS and +10.8% for AGIO. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, ABUS or AGIO?

ABUS is the better-valued of the two on the peer-relative Value factor. ABUS on the peer-relative Value factor, by 40 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, ABUS or AGIO?

AGIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, ABUS or AGIO?

AGIO on the Momentum factor, by 10 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, ABUS or AGIO?

ABUS is the more resilient of the two, so the other name carries the higher downside risk. ABUS on Risk Resilience, by 15 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is ABUS more profitable than AGIO?

ABUS leads on the comparable margin measures — gross margin 100% vs 91.9%; operating margin 79.9% vs -297.7%; ttm roe 68.9% vs -6.6%.

Is ABUS's lead over AGIO getting stronger or weaker?

ABUS lead: Weakening — the AIQ differential moved from 19 to 14 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the ABUS vs AGIO verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: AGIO closes the Value gap — currently 40 points behind, the largest single contributor to ABUS's edge; AGIO's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; ABUS's conflicting signal state resolves bearish — it currently carries 2 bullish and 3 bearish rules at once; the narrowing continues — the lead has already given back 5 points over 30 sessions, and a further 14-point move would eliminate ABUS's advantage entirely.

What do the current signals say about ABUS and AGIO?

ABUS: 2 bullish / 3 bearish / 1 neutral, conflicted. AGIO: 1 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on ABUS is Death Cross Active (bearish, long horizon). On AGIO it is Golden Cross Active (bullish, long horizon).

Compare ABUS and AGIO with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.